Cancers Review

Published by: Asian Medical Jo
Online ISSN: 2408-9273
Print ISSN: 2409-2053
Quick Submission    Login/Submit/Track

No. 2

Prosthodontic Rehabilitatative Therapy through Surgical Obturator for Maxillectomy Patients: A Review

Pages: 52-58
Find References

Finding References


Prosthodontic Rehabilitatative Therapy through Surgical Obturator for Maxillectomy Patients: A Review

Search :
Google Scholor
Search :
Microsoft Academic Search
Cite

DOI: 10.18488/journal.95/2014.1.2/95.2.52.58

Citation: 2

Manu Rathee , Mohaneesh Bhoria , Poonam Malik

Export to    BibTeX   |   EndNote   |   RIS

  1. S. Warnakulasuriya, "Global epidemiology of oral and oropharyngeal cancer," Oral Oncology, vol. 45, pp. 309–316, 2009.
  2. K. Alibek, A. Kakpenova, and Y. Baiken, "Role of infectious agents in the carcinogenesis of brain and head and neck cancers," Infectious Agents and Cancer, vol. 8, pp. 7-10, 2013.
  3. S. Warnakulasuriya, "Causes of oral cancer—an appraisal of controversies," British Dental Journal, vol. 207, pp. 471–475, 2009.
  4. P. Bose, N. T. Brockton, and J. C. Dort, "Head and neck cancer: From anatomy to biology," International Journal of Cancer, vol. 133, pp. 2013–2023, 2013.
  5. Glossary of prosthodontic terms, J Prosthet Dent, vol. 94, pp. 10-92, 2005.
  6. R. Michael, Arcuri, and T. D. Taylor, Clinical managemnt of the dentate maxillectomy patient. Clinical maxillofacial prosthetics: 1st Quintessence Publishing Co,Inc, 2000.
  7. H. Schliephake and M. Jamil, "Prospective evaluation of quality of life after oncologic surgery for oral cancer," Int J Oral Maxillofac Surg., vol. 31, pp. 427–433, 2002.
  8. K. Shepherd and S. Fisher, "Prospective evaluation of quality of life in patients with oral and oropharyngeal cancer: From diagnosis to three months post-treatment," Oral Oncol, vol. 40, pp. 751–757, 2004.
  9. S. Rogers, D. Lowe, and G. Humphris, "Distinct patient groups in oral cancer: A prospective study of perceived health status following primary surgery," Oral Oncol, vol. 36, pp. 529–538, 2000.
  10. J. Beumer, D. Curtis, and D. Firtell, Restoration of acquired hard palate defects. In maxillofacial rehabilitation: Prosthodontic and surgical considerations. St. Louis: Mosby, 1979.
  11. B. Lethaus, N. Lie, and F. De Beer, "Surgical and prosthetic reconsiderations in patients with maxillectomy," J Oral Rehabil, vol. 37, pp. 138-42, 2010.
  12. G. Parr, "Prosthodontic principles in the framework design of maxillary obturator prosthesis," J Prosthet Dent., vol. 62, pp. 205–12, 1989.
  13. M. Aramany, "Basic principles of obturator design for partially edentulous patients part 1: Classification," J Prosthet Dent., vol. 40, pp. 554–7, 1978.
  14. M. Aramany, "Basic principles of obturator design for partially edentulous patients part 11: Design principles," J Prosthet Dent., vol. 40, pp. 656–62, 1978.
  15. S. Rogers, "Health related quality of life after maxillectomy: A comparison between prosthetic obturation and free flap," J Oral Maxillofacial Surg., vol. 61, pp. 174–81, 2003.
  16. J. Beumer, T. Curtis, and D. Firtell, Maxillofacial rehabilitation. St. Louis: Mosby, 1979.
  17. R. Des Jardius, "Obturator prosthesis design for acquired maxillectomy defects," J Prosthet Dent., vol. 39, pp. 424–35, 1978.
  18. M. Earley, "Primary maxillary reconstruction after cancer excision," Br J Plast Surg., vol. 42, pp. 628-37, 1989.
  19. S. Sakai, H. Fuchihata, and Y. Hamasaki, "Treatment policy for maxillary sinus carcinoma," Acta Otolaryngol., vol. 82, pp. 172-81, 1976.
  20. G. R. Parr, "Prosthodontic principles in the framework design of maxillary obturator prosthesis," J Prosthet Dent., vol. 62, pp. 205–12, 1989.
  21. R. Spiro, E. Strong, and J. Shah, "Maxillectomy and its classification," Head Neck, vol. 19, pp. 309-14, 1997.
  22. S. Davison, D. Sherris, and N. Meland, "An algorithm for maxillectomy defect  reconstruction," Laryngoscope, vol. 108, pp. 215-9, 1998.
No any video found for this article.
Manu Rathee , Mohaneesh Bhoria , Poonam Malik (2014). Prosthodontic Rehabilitatative Therapy through Surgical Obturator for Maxillectomy Patients: A Review. Cancers Review, 1(2): 52-58. DOI: 10.18488/journal.95/2014.1.2/95.2.52.58
The maxillofacial patient experiences a unique alteration in the normal oral/craniofacial environment and functions, which are the results of congenital, traumatic or surgical insults. Maxillofacial Prosthetics aimed to attain the optimal functions, such as speech and swallowing, and normalcy of surrounding structure. The provision of surgical obturator is one step in achieving normalcy, as it allows covering the deficiencies/defects to regain optimal/suboptimal functions immediately after surgical resection. This paper provides an overview on the designing principles, goals and role of surgical obturator in rehabilitating maxillectomy cases.
Contribution/ Originality

Role of Iron Metabolism in Breast Cancer Patients

Pages: 45-51
Find References

Finding References


Role of Iron Metabolism in Breast Cancer Patients

Search :
Google Scholor
Search :
Microsoft Academic Search
Cite

DOI: 10.18488/journal.95/2014.1.2/95.2.45.51

Citation: 2

Rakesh Dhankhar , Adarsh C , Kiran Dahiya , Veena Singh Ghalaut , Nityasha . , Anil Kumar Dhull , Anil Khurana

Export to    BibTeX   |   EndNote   |   RIS

  1. D. ?uji?, I. Stefanoska, and S. Golubovi?, "Serum ferritin in healthy women and breast cancer patients," J Med Biochem., vol. 30, pp. 33-37, 2011.
  2. J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, "Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008," Int J Cancer, vol. 127, pp. 2893-2917, 2010.
  3. B. P. Das, "Cancer patterns in Haryana: Twenty-one years’ experience," Radiation Oncology, vol. 5, pp. 22-32, 2005.
  4. R. Sauer, "Adjuvant radiotherapy after breast consrving surgery for breast cancer," Pro Eur J Cancer, vol. 36, pp. 1073-1078, 2000.
  5. J. G. Liehr and J. S. Jones, "Role of iron in estrogen-induced cancer," Curr Med Chem., vol. 8, pp. 839-849, 2001.
  6. O. Marques, B. M. Da Silva, G. Porto, and C. Lopes, "Iron homeostasis in breast cancer," Cancer Lett., vol. 34, pp. 1-14, 2014.
  7. C. A. Finch and H. A. Huebers, "Iron metabolism," Clin Physiol Biochem., vol. 4, pp. 5-10, 1986.
  8. A. Jacobs, B. Jones, C. Ricketts, R. D. Bulbrook, and D. Y. Wang, "Serum ferritin concentration in early breast cancer," Br J Cancer, vol. 34, pp. 286-289, 1976.
  9. M. H. Doner, A. Silverstone, K. Nishiya, A. De Sostoa, and M. De Sousa, "Ferritin synthesis by T lymphocytes," Science, vol. 209, pp. 1019-1021, 1980.
  10. T. N. Tran, S. K. Eubanks, K. J. Schaffer, C. Y. Zhou, and M. C. Linder, "Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron," Blood, vol. 90, pp. 4979-4986, 1997.
  11. A. M. Dupuy, L. Debarge, M. Poulain, S. Badiou, M. Rossi, and J. P. Cristol, "Determination of serum ferritin using immunoturbidimetry or chemiluminescent detection in comparison with radioimmunoassay- a compendium of a methodological juxtaposition," Clin Lab., vol. 55, pp. 207-215, 2009.
  12. A. Ellervik, H. A. Tybaerg, M. Appleyard, H. Ibsen, and B. G. Nordestgaard, "Haemochromatosis genotype and iron overload: Association with hypertension and left ventricular hypertrophy," J Intern Med., vol. 268, pp. 252-264, 2010.
  13. J. G. Liehr and J. S. Jones, "S. Role of iron in estrogen-induced cancer," Curr Med Chem., vol. 8, pp. 839-849, 2001.
  14. R. G. Stevens, J. B. Cologne, K. Nakachi, E. J. Grant, and K. Neriishi, "Body iron stores and breast cancer risk in female atomic bomb survivors," Cancer Sci., vol. 102, pp. 2236-2240, 2011.
  15. A. J. Cross, M. J. Gunter, R. J. Wood, P. Pietinen, P. R. Taylor, and J. Virtamo, "Iron and colorectal cancer risk in the alpha-tocopherol, beta-carotene cancerprevention study," Int J Cancer, vol. 118, pp. 3147-3152, 2006.
  16. J. Wish, "Assessing iron status: Beyond serum ferritin and transferrin saturation," Clin J Am Soc Nephrol., vol. Suppl 1, pp. S4-8, 2006.
  17. S. V. Torti and F. M. Torti, "Cellular iron metabolism in prognosis and therapy of breast cancer," Crit Rev Oncogen, vol. 18, pp. 435-448, 2013.
  18. V. F. Chekhun, N. Y. Lukyanova, C. A. Burlaka, N. A. Bezdenezhnykh, S. I. Shpyleva, and V. P. Tryndyak, "Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin," Int J Oncol., vol. 43, pp. 1481-1486, 2013.
  19. J. L. Heath, J. M. Weiss, C. P. Lavau, and D. S. Wechsler, "Iron deprivation in cancer- potential therapeutic implications," Nutrients, vol. 5, pp. 2836-2859, 2013.
  20. M. A. Ali, A. Akhmedkhanov, A. Zeleniuch-Jaquotte, P. Toniolo, K. Frenkel, and X. Huang, "Reliability of serum iron, ferritin, nitrite and association with risk of renal cancer in women," Cancer Detect Prev., vol. 27, pp. 116-121, 2003.
  21. R. Rossiello, M. V. Carriero, and G. G. Giordano, "Distribution of ferritin, transferrin and lactoferrin in breast carcinoma tissue," J Clin Pathol., vol. 37, pp. 51-55, 1984.
  22. G. A. Colditz, "Epidemiology and prevention of breast cancer," Cancer Epidemiol Biomarkers Prev., vol. 14, pp. 768-772, 2005.
Rakesh Dhankhar , Adarsh C , Kiran Dahiya , Veena Singh Ghalaut , Nityasha . , Anil Kumar Dhull , Anil Khurana (2014). Role of Iron Metabolism in Breast Cancer Patients. Cancers Review, 1(2): 45-51. DOI: 10.18488/journal.95/2014.1.2/95.2.45.51
Iron metabolism is closely related to carcinogenesis. In this study, iron, ferritin and TIBC were analysed in 30 patients of early stage, 30 of advanced stage breast carcinoma before and after treatment and the results were compared with 30 healthy controls. The levels of all the three parameters were found to be significantly higher in breast cancer patients as compared to healthy controls and patients with advanced disease showed greater values as compared to early stage disease. These levels decreased after treatment and the difference was more significant in patients with complete response. Serum analyses of iron, ferritin and TIBC may help in assessing the severity and prognosis of the disease.
Contribution/ Originality
This study contributes in the existing literature regarding association of iron metabolism and carcinogenesis. The principal role of iron profile analysis may be in asessing the severity and monitoring the treatment of breast cancer patients.

Clinical Significance of Salivary Matrix Metalloproteinase-9 in Oral Precancerous Conditions and Oral Cancer

Pages: 33-44
Find References

Finding References


Clinical Significance of Salivary Matrix Metalloproteinase-9 in Oral Precancerous Conditions and Oral Cancer

Search :
Google Scholor
Search :
Microsoft Academic Search
Cite

DOI: 10.18488/journal.95/2014.1.2/95.2.33.44

Citation: 3

Bhairavi N. Vajaria , Kinjal R. Patel , Rasheedunnisa Begum , Franky D. Shah , Jayendra B. Patel , Geeta M. Joshi , Prabhudas S. Patel

Export to    BibTeX   |   EndNote   |   RIS

  1. Z. Khan, "An overview of oral cancer in Indian subcontinent and recommendations to decrease its incidence," Webmed Central Cancer, vol. 3, pp. 1-29, 2012.
  2. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, "Global cancer statistics," CA Cancer J. Clin., vol. 61, pp. 69-90, 2011.
  3. A. Gialeli, A. D. Theocharis, and N. K. Karamanaos, "Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting," FEBS J., vol. 278, pp. 16-27, 2011.
  4. R. Roy, J. Yang, and M. Moses, "Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer," J. Clin. Oncol., vol. 27, pp. 5287-5297, 2009.
  5. P. Vihenen and V. M. Kahari, "Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets," Int. J. Cancer, vol. 99, pp. 157-166, 2002.
  6. M. H. Shah, R. N. Sainger, S. D. Telang, G. I. Pancholi, S. N. Shukla, and P. S. Patel, "E-cadherin and sialyl lewis-x overexpression in oral squamous cell carcinoma and oral precancerous conditions," Neoplasma, vol. 56, pp. 40-47, 2009.
  7. B. P. Patel, P. M. Shah, U. M. Rawal, A. M. Desai, S. V. Shah, and R. M. Rawal, "Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma," J. Surg. Oncol., vol. 90, pp. 81-88, 2005.
  8. R. D. Singh, H. Nilayangode, J. B. Patel, F. D. Shah, S. N. Shukla, and P. M. Shah, "Combined evaluation of matrix metalloproteinases and their inhibitors has better clinical utility in oral cancer," Int. J. Biol. Markers, vol. 26, pp. 27-36, 2011.
  9. R. D. Singh, N. Haridas, J. B. Patel, S. N. Shukla, P. M. Shah, and P. S. Patel, "Matrix metalloproteinases and their inhibitors: Correlation with invasion and metastasis in oral cancer," Indian J. Clin. Biochem., vol. 25, pp. 250-259, 2010.
  10. R. C. Jordan, M. Macabeo-Ong, C. H. Shiboski, N. Dekker, D. G. Ginzinger, and D. T. Wong, "Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer," Clin. Cancer Res., vol. 10, pp. 6460-6465, 2004.
  11. A. U. Nair, R. Thavarajah, and K. Ranganathan, "Saliva and dental practice," J. NTR Univ Health Sci., vol. 1, pp. 72-76, 2012.
  12. D. T. W. Wong, "Salivaomics," J. Am. Dent. Assoc., vol. 143, pp. 19S-24S, 2012.
  13. T. Pfaffe, J. Cooper-White, P. Beyerlien, K. Kostner, and C. Punyadeera, "Diagnostic potential of saliva: current state and future applications," Clin. Chem., vol. 57, pp. 675-87, 2011.
  14. Y. Miyoshi, M. Watanabe, and N. Takahashi, "Autoactivation of proteolytic activity in human whole saliva," J. Oral Biosci., vol. 52, pp. 402-408, 2010.
  15. F. I. Greene, D. L. Page, and I. D. Fleming, American joint committee on cancer (AJCC). Head and neck sites. In: Cancer staging manual, 6th ed. Philadelphia, PA: JB Lippincott, 2002.
  16. S. Hu, J. Wang, J. Meijer, S. Ieong, Y. Xie, and T. Yu, "Salivary proteomic and genomic biomarkers for primary sjogren’s syndrome," Arthritis Rheum, vol. 56, pp. 3588-3600, 2007.
  17. O. H. Lowry, N. J. Rosenbrough, A. L. Farr, and R. J. Randall, "Protein measurement with the folin phenol reagent," J. Biol. Chem., vol. 193, pp. 265-275, 1951.
  18. J. A. Lorenzo, C. C. Pilbeam, J. F. Kalinowski, and M. S. Hibbs, "Production of both 92 kDa and 72 kDa gelatinases by bone cells," Matrix, vol. 12, pp. 282-289, 1992.
  19. D. Peschos, C. Damala, D. Stefanou, E. Tsanou, D. Assimakopoulos, and T. Vougiouklakis, "Expression of matrix metalloproteinase -9 (Gelatinase B) in benign, premalignant and malignant laryngeal lesions," Histo. Histopathol., vol. 21, pp. 603-608, 2006.
  20. R. P. Goncalves, C. A. Damante, F. L. S. Lima, A. V. Imbronito, F. D. Nunes, and F. E. Pustiglioni, "Detection of MMP-2 and MMP-9 salivary levels in patients with chronic periondontitis before and after periodontal treatment," Rev. Odonto Cienc., vol. 24, pp. 264-269, 2009.
  21. T. Ingman, T. Sorsa, O. Lindy, H. Koski, and T. Konttinen, "Multiple forms of gelatinases /type IV collagenases in saliva and gingival crevicular fluid of periodontitis patients," J. Clin. Periodontal, vol. 21, pp. 26-31, 1994.
  22. S. Triebel, J. Blaser, H. Relinke, and H. Tschesche, "A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase," FEBS Lett., vol. 314, pp. 386-388, 1992.
  23. S. Y. Liu, M. H. Lin, S. C. Yang, G. C. Huang, L. Chang, and S. Chang, "Areca quid chewing enhances the expression of salivary matrix metalloproteinase-9," J. Formos Med. Assoc., vol. 104, pp. 113-119, 2005.
  24. C. T. Chiu, C. Y. Chuang, S. W. Chang, S. Y. Lee, D. J. Wang, and Y. C. Liu, "Expression of matrix metalloproteinases in oral cancer patients who are betel quid users," Taiwan J. Oral Maxillofac. Surg., vol. 19, pp. 313-327, 2009.
  25. S. D. Hong, S. P. Hong, J. I. Lee, and C. Y. Lim, "Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinoma with regard to the metastatic potential," Oral Oncol., vol. 36, pp. 207-213, 2000.
Bhairavi N. Vajaria , Kinjal R. Patel , Rasheedunnisa Begum , Franky D. Shah , Jayendra B. Patel , Geeta M. Joshi , Prabhudas S. Patel (2014). Clinical Significance of Salivary Matrix Metalloproteinase-9 in Oral Precancerous Conditions and Oral Cancer. Cancers Review, 1(2): 33-44. DOI: 10.18488/journal.95/2014.1.2/95.2.33.44
Background: Oral cancer is a one of the major health burden worldwide and also in India. The most strenuous problem in oral cancer is metastasis, where use of newer non-invasive biomarkers for early detection of metastatic tumors would be greatly helpful. Aim: The aim was to evaluate salivary matrix metalloproteinase-9 in patients with oral precancerous conditions (OPC) and oral cancer to assess its utility in monitoring oral cancer progression. Subjects and Methods: Total 250 subjects including 100 controls, 50 patients with OPC and 100 oral cancer patients were enrolled for the study. Gelatin zymography was performed for the evaluation of matrix metalloproteinase (MMP)-9 and truncated 42 kDa MMP. Statistical Analysis: Statistical analysis like Student’s independent‘t’ test, Receiver’s Operating Characteristic (ROC) curve, correlation and multivariate analysis were performed to analyze the results. Results: A truncated form of MMP i.e. 42 kDa was observed to have gelatinolytic activity. An increasing trend of salivary pro MMP-9, active MMP-9, MMP-9 activation ratio and truncated 42 kDa MMP was observed from controls to patients with OPC to oral cancer patients. ROC curve analysis revealed that all forms of MMPs could significantly discriminate controls and oral cancer patients; moreover, pro MMP-9 and active MMP-9 significantly distinguished patients with OPC and oral cancer patients. All the levels were found to be higher in patients with advanced disease and with metastasis as compared to patients with early disease and without metastasis, respectively. Conclusion: Elevated levels of salivary MMP-9 and truncated 42 kDa MMP in patients with OPC and oral cancer may be important for assessing early changes occurring during neoplastic transformation of oral cancer.
Contribution/ Originality